Hereditary Angioedema Therapeutics Market

• Increasing awareness of HAE among the populations to boost the market growth

The increasing awareness of HAE among populations is a significant driver of market expansion. As per the Department of Health & Social Care, people are continuously aware of the hereditary angioedema disease and their effective treatment. The Health & Social Care Department of UK has worked with the four nations to confirm that hereditary angioedema disease patients receive better diagnosis and treatment care. In addition, many companies are also keenly interested in launching hereditary angioedema awareness programs. 

For instance: in May 2023 Takeda Biopharmaceuticals India launched the hereditary angioedema awareness program “Sunrise Patient Services Program (PSP)’ for Hereditary Angioedema (HAE) patients in India. This program aims to provide patient support on four main elements including screening & diagnosis, treatment, and maintenance support applied, quality diagnostic labs, treatment compensation navigation, and lifestyle counseling support during the patient’s treatment journey. 

Furthermore, In 16 May 2022, HAE Awareness Day was pragmatic across the globe to increase awareness about hereditary angioedema (HAE) and those patients the disorder affects. The aim is to raise awareness among the population as well as industry representatives, and healthcare professionals. With the help of this HAE Awareness Day developed an atmosphere for accurate and early diagnosis as well as improved HAE patient care, an Awareness Day webpage states. So that patients can get a better quality of life. 

The global HAE awareness efforts were being led by HAE International (HAEi), which is an international network of patient organizations that look to improve the quality of life of HA patients. At present time HAEi supports 93 member organizations across the globe. Thus rising awareness programmes by government and private institutions play a key role in early diagnosis and better therapeutics for hereditary angioedema disease of patients which is propel the market growth of the hereditary angioedema therapeutics.

The Global Hereditary Angioedema Therapeutics Market Industry is projected to experience robust growth, with estimates indicating a market value of 7.39 USD billion in 2024 and a potential increase to 15.4 USD billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 6.9% from 2025 to 2035, reflecting the increasing demand for effective therapeutic options. The market dynamics are influenced by various factors, including advancements in treatment modalities, regulatory support, and the rising prevalence of hereditary angioedema.

Increased awareness regarding hereditary angioedema among healthcare professionals and patients is a crucial factor driving the Global Hereditary Angioedema Therapeutics Market Industry. Educational initiatives and advocacy efforts have led to improved recognition of symptoms, resulting in timely diagnosis and treatment. This heightened awareness is likely to lead to a surge in diagnosed cases, thereby increasing the demand for effective therapeutics. As a result, the market is expected to experience a compound annual growth rate (CAGR) of 6.9% from 2025 to 2035, reflecting the growing need for comprehensive management strategies.

Innovations in therapeutic approaches for hereditary angioedema are significantly shaping the Global Hereditary Angioedema Therapeutics Market Industry. Recent developments include the introduction of targeted therapies, such as C1-inhibitor replacement therapies and bradykinin receptor antagonists, which have shown promising results in clinical trials. These advancements not only enhance treatment efficacy but also reduce the frequency of attacks, thereby improving patient adherence to therapy. As the market evolves, it is anticipated that the industry will expand, potentially reaching 15.4 USD billion by 2035, driven by the continuous introduction of novel therapies.

The expansion of healthcare infrastructure in emerging markets is poised to impact the Global Hereditary Angioedema Therapeutics Market Industry positively. Countries in Asia-Pacific and Latin America are witnessing improvements in healthcare access and affordability, which may facilitate the diagnosis and treatment of hereditary angioedema. As these regions develop, they are likely to adopt advanced therapeutic options, thereby increasing the overall market size. This trend is expected to contribute to the anticipated growth trajectory, with the market projected to reach 15.4 USD billion by 2035.

Regulatory bodies are increasingly supportive of the development and approval of new therapies for hereditary angioedema, which is a significant driver for the Global Hereditary Angioedema Therapeutics Market Industry. Fast-track designations and orphan drug status granted to innovative treatments expedite their availability to patients. This regulatory environment encourages pharmaceutical companies to invest in research and development, leading to a broader range of treatment options. As these therapies enter the market, they are expected to contribute to the overall growth of the industry, aligning with the projected market value of 7.39 USD billion in 2024.

The rising incidence of hereditary angioedema (HAE) globally is a primary driver for the Global Hereditary Angioedema Therapeutics Market Industry. Reports indicate that approximately 1 in 50,000 individuals are affected by this rare genetic disorder, leading to a growing patient population in need of effective therapies. As awareness increases, more patients are being diagnosed, which is expected to contribute to market growth. The market is projected to reach 7.39 USD billion in 2024, reflecting the urgent need for innovative treatment options that can manage symptoms and improve the quality of life for patients.

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Hereditary Angioedema Therapeutics market is expected to account for USD 1.4 billion in 2022 and is expected to exhibit an 14.12% CAGR during the study period. This is attributed to the market of Hereditary Angioedema therapeutics is well-established and witnesses continuous growth. This region boasts advanced healthcare facilities and high awareness of rare diseases like HAE. The demand for prophylactic treatments, especially long-term prophylaxis, remains significant, as patients prefer preventive measures to reduce the frequency and severity of attacks. 

The market also observes a growing preference for selective bradykinin B2 receptor antagonists, which offer oral alternatives for both prophylaxis and on-demand treatment. Intravenous administration is prevalent for immediate relief during acute attacks in the region further fuel the growth of the market. Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: Hereditary Angioedema Therapeutics Market share by region 2022 & 2032 (USD billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Hereditary Angioedema Therapeutics market is expected to account for the second-largest market share due to the rising research and development actvitity, rising product approval and favourable reimbursement policy for orphan drugs older population. Further, the Germany market of Hereditary Angioedema Therapeutics is expected to hold third place for the market share, and the UK market of Hereditary Angioedema Therapeutics is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France market of Hereditary Angioedema Therapeutics will hold the 5th place for the market share.

The Asia-Pacific Hereditary Angioedema Therapeutics market is expected to grow at a high growth rate from 2023 to 2032. This is due to the rising disposable income in the developing countries and availability of medical facility and medical staff,rising awareness programe launch. Moreover, China market of Hereditary Angioedema Therapeutics is expected to hold the largest market share, and the India market of Hereditary Angioedema Therapeutics is expected fastest-growing market in the Asia-Pacific region.

The Rest of the World includes the Middle East, Africa, and Latin America. Government initiatives to increase medical expenditure and increase healthcare infrastructure in the region contribute to the growth of the rest of the world market of Hereditary Angioedema Therapeutics.

The presence of major market players in the Hereditary Angioedema Therapeutics Market is characterized by the presence of many international, regional, and local players. The companies are investing in R&D activities to expand their product portfolio for breast enhancement, which further drives the market growth of the Hereditary Angioedema Therapeutics. Moreover, the vendors compete based on cost, product quality, reliability, and aftermarket services and try to be the first to bring treatment for the public. It is crucial for the players to offer cost-efficient and high-quality products for Hereditary Angioedema Therapeutics to succeed in an intensely competitive market environment.

One of the primary business strategies adopted by manufacturers in the global Hereditary Angioedema Therapeutics industry to benefit clients and expand the market sector of Hereditary Angioedema Therapeutics is to manufacture locally to reduce operating costs.

Sanofi is a global life science company concentrating on improving access to healthcare and supporting the people throughout the continuum of care. From prevention to treatment, the company transforms scientific innovation into healthcare solutions in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, and consumer healthcare. The company is present in more than 170 countries, and it has 37 manufacturing units in 36 countries.